IntegraGen SA (ALINT.PA)
EUR 0.53
(0.0%)
EUR 0.53
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 311.44 Thousand EUR | -21.53% |
| 2022 | 396.92 Thousand EUR | 15.86% |
| 2021 | 342.58 Thousand EUR | 44.01% |
| 2020 | 237.88 Thousand EUR | -17.97% |
| 2019 | 290 Thousand EUR | -25.4% |
| 2018 | 388.73 Thousand EUR | 7.96% |
| 2017 | 360.06 Thousand EUR | -4.72% |
| 2016 | 377.91 Thousand EUR | 40.82% |
| 2015 | 268.37 Thousand EUR | -21.16% |
| 2014 | 340.41 Thousand EUR | 45.27% |
| 2013 | 234.33 Thousand EUR | 18.51% |
| 2012 | 197.74 Thousand EUR | 10.08% |
| 2011 | 179.63 Thousand EUR | 93.29% |
| 2010 | 92.93 Thousand EUR | -74.58% |
| 2009 | 365.61 Thousand EUR | 69.07% |
| 2008 | 216.25 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 334 Thousand EUR | 0.0% |
| 2023 Q2 | 524.71 Thousand EUR | 0.0% |
| 2023 FY | 311.44 Thousand EUR | -21.53% |
| 2023 Q4 | 311.44 Thousand EUR | 0.0% |
| 2022 Q4 | 396.92 Thousand EUR | 0.0% |
| 2022 Q2 | 451.19 Thousand EUR | 0.0% |
| 2022 FY | 396.92 Thousand EUR | 15.86% |
| 2021 Q4 | 342 Thousand EUR | 0.0% |
| 2021 FY | 342.58 Thousand EUR | 44.01% |
| 2021 Q2 | 348 Thousand EUR | 0.0% |
| 2020 FY | 237.88 Thousand EUR | -17.97% |
| 2020 Q2 | 455.47 Thousand EUR | 0.0% |
| 2020 Q4 | 237.88 Thousand EUR | 0.0% |
| 2019 Q4 | 290 Thousand EUR | 0.0% |
| 2019 Q2 | 319.24 Thousand EUR | 0.0% |
| 2019 FY | 290 Thousand EUR | -25.4% |
| 2018 Q2 | 309.47 Thousand EUR | 0.0% |
| 2018 FY | 388.73 Thousand EUR | 7.96% |
| 2018 Q4 | 388.73 Thousand EUR | 0.0% |
| 2017 Q2 | 373.4 Thousand EUR | 0.0% |
| 2017 FY | 360.06 Thousand EUR | -4.72% |
| 2017 Q4 | 360.06 Thousand EUR | 0.0% |
| 2016 Q2 | 342.57 Thousand EUR | 0.0% |
| 2016 Q4 | 377.91 Thousand EUR | 0.0% |
| 2016 FY | 377.91 Thousand EUR | 40.82% |
| 2015 Q2 | 460.39 Thousand EUR | 0.0% |
| 2015 FY | 268.37 Thousand EUR | -21.16% |
| 2015 Q4 | 268.37 Thousand EUR | 0.0% |
| 2014 Q4 | 340.41 Thousand EUR | 0.0% |
| 2014 FY | 340.41 Thousand EUR | 45.27% |
| 2014 Q2 | 227.13 Thousand EUR | 0.0% |
| 2013 Q4 | 234.33 Thousand EUR | 0.0% |
| 2013 FY | 234.33 Thousand EUR | 18.51% |
| 2013 Q2 | 382.87 Thousand EUR | 0.0% |
| 2012 Q4 | 197.74 Thousand EUR | 0.0% |
| 2012 Q2 | 230.16 Thousand EUR | 0.0% |
| 2012 FY | 197.74 Thousand EUR | 10.08% |
| 2011 FY | 179.63 Thousand EUR | 93.29% |
| 2011 Q2 | 92.93 Thousand EUR | 0.0% |
| 2011 Q4 | 179.63 Thousand EUR | 0.0% |
| 2010 Q4 | 92.93 Thousand EUR | 0.0% |
| 2010 FY | 92.93 Thousand EUR | -74.58% |
| 2010 Q2 | 495.15 Thousand EUR | 0.0% |
| 2009 FY | 365.61 Thousand EUR | 69.07% |
| 2008 FY | 216.25 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -40.927% |
| ABIVAX Société Anonyme | 1.00 EUR | -31144800.0% |
| Adocia SA | 272 Thousand EUR | -14.503% |
| Aelis Farma SA | 53 Thousand EUR | -487.64% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | 82.111% |
| genOway Société anonyme | 982.75 Thousand EUR | 68.308% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -89.19% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 128.092% |
| Plant Advanced Technologies SA | 1.22 Million EUR | 74.567% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 361.335% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -242.252% |
| Valbiotis SA | 1 Million EUR | 69.01% |
| TheraVet SA | 123.34 Thousand EUR | -152.508% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -31144800.0% |
| argenx SE | 281.12 Million EUR | 99.889% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | 75.282% |
| DBV Technologies S.A. | 1.00 USD | -31144800.0% |
| Galapagos NV | 73.97 Million EUR | 99.579% |
| Genfit S.A. | 4000.00 EUR | -7686.225% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -31144800.0% |
| Innate Pharma S.A. | 1.00 EUR | -31144800.0% |
| Inventiva S.A. | 417 Thousand EUR | 25.312% |
| MaaT Pharma SA | 190 Thousand EUR | -63.921% |
| MedinCell S.A. | -6.71 Million EUR | 104.639% |
| Nanobiotix S.A. | 200 Thousand EUR | -55.725% |
| Onward Medical N.V. | 936 Thousand EUR | 66.726% |
| Oryzon Genomics S.A. | 6029.00 EUR | -5065.848% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -143.32% |
| Pharming Group N.V. | 51.38 Million EUR | 99.394% |
| Poxel S.A. | 2.95 Million EUR | 89.464% |
| GenSight Biologics S.A. | 1.00 EUR | -31144800.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 99.97% |
| Valneva SE | 44.46 Million EUR | 99.3% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -31144800.0% |